Payment overview · 2025
General Payments
$393.71
24 reported records · 9 companies
Healthcare provider profile · identity verified
Zoe Michelle Walker, MD
Allopathic & Osteopathic Physicians|Family Medicine · GATESVILLE, TX · NPI 1184987406
Verified facts
What the public records show
CMS Open Payments records show Zoe Michelle Walker, MD received $393.71 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 37.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.09 | 37.4% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.00 | 17.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.88 | 12.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.95 | 9.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.24 | 7.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.61 | 4.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.92 | 3.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.39 | 3.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.63 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $393.71 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.31 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.31 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.78 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.88 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.88 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.24 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
168 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 377 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 289 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 69 |
| Gabapentin | Gabapentin | 262 | 54 |
| Potassium Chloride | Potassium Chloride | 220 | 46 |
| Lisinopril | Lisinopril | 193 | 50 |
| Mounjaro | Tirzepatide | 168 | 24 |
| Furosemide | Furosemide | 157 | 33 |
| Losartan Potassium | Losartan Potassium | 145 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 28 |
| Ozempic | Semaglutide | 138 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 29 |
| Sertraline Hcl | Sertraline Hcl | 119 | 24 |
| Trazodone Hcl | Trazodone Hcl | 119 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 41 |
| Tramadol Hcl | Tramadol Hcl | 114 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 26 |
| Mirtazapine | Mirtazapine | 113 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 111 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 27 |
| Bupropion Xl | Bupropion Hcl | 97 | 20 |
| Montelukast Sodium | Montelukast Sodium | 84 | 18 |
| Buspirone Hcl | Buspirone Hcl | 82 | 19 |
| Pregabalin | Pregabalin | 78 | suppressed |
| Ezetimibe | Ezetimibe | 76 | 20 |
| Omeprazole | Omeprazole | 75 | 21 |
| Eliquis | Apixaban | 71 | 15 |
| Carvedilol | Carvedilol | 69 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 19 |
| Metformin Hcl | Metformin Hcl | 67 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 63 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 16 |
| Alprazolam | Alprazolam | 60 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 19 |
| Simvastatin | Simvastatin | 54 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 14 |
| Allopurinol | Allopurinol | 51 | 11 |
| Metformin Hcl Er | Metformin Hcl | 49 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Prednisone | Prednisone | 47 | 32 |
| Alendronate Sodium | Alendronate Sodium | 45 | 15 |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Jardiance | Empagliflozin | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 12 |
| Atenolol | Atenolol | 38 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Torsemide | Torsemide | 33 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Jantoven | Warfarin Sodium | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $393.71 · 24 records | ABBVIE INC. | BREZTRI, CAPVAXIVE, Cologuard Collection Kit, FARXIGA, GARDASIL 9, KEVEYIS, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VAXNEUVANCE, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error